|IUPAC name|| (2R,6S,11S)-3-(cyclopropylmethyl)-3,4,5,|
|Molar mass||285.381 g/mol|
| Except where noted otherwise, data are given for|
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references
Ketazocine (INN) (Ketocyclazocine) is a cyclazocine derivative used in opioid receptor research. Ketocyclazocine is an exogenous (not naturally produced by the body) opioid that binds to the kappa opioid receptor.
Activation of this receptor causes a decrease in pain sensations and increased sleepiness but can also cause psychological symptoms such as feelings of unease, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous (produced by the body) substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)
Unlike other opioids, substances that only bind to the kappa receptor theoretically do not impair the normal drive to breathe.
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies